GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax

  • Authors:
    • Kateřina Vlčková
    • Jiri Réda
    • Lubica Ondrušová
    • Mohammad Krayem
    • Ghanem Ghanem
    • Jiri Vachtenheim
  • View Affiliations

  • Published online on: July 1, 2016     https://doi.org/10.3892/ijo.2016.3596
  • Pages: 953-960
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MEK kinase inhibitors (trametinib and selumetinib) or kinase inhibitors directed against mutated BRAF(V600E) (vemurafenib and dabrafenib) have initial encouraging effects in the treatment of melanoma but acquired resistance appears almost invariably after some months. Studies revealed mutually exclusive NRAS and BRAF activating mutations driving the MAPK/ERK pathway among human melanomas. Although combination therapy exerts significantly better antitumor cell efficacy, complete remission is rarely achieved. To employ an alternative approach, we have targeted the Hedgehog/GLI pathway, which is deregulated in melanomas, through the GLI1/2 inhibitor GANT61, alone or accompanied with the treatment by the BCL2 family inhibitor obatoclax in 9 melanoma cell lines. Thus, we targeted melanoma cells irrespective of their NRAS or BRAF mutational status. After GANT61 treatment, the cell viability was drastically diminished via apoptosis, as substantial nuclear DNA fragmentation was detected. In all tested melanoma cell lines, the combined treatment was more efficient than the application of each drug alone at the end of the cell growth with inhibitors. GANT61 was efficient also alone in most cell lines without the addition of obatoclax, which had only a limited effect when used as a single drug. In most cell lines, tumor cells were eradicated after 5-9 days of combined treatment in colony outgrowth assay. To conclude, GANT61 treatment might become a hopeful and effective anti-melanoma targeted therapy, especially when combined with the BCL2 family inhibitor obatoclax.
View Figures
View References

Related Articles

Journal Cover

September 2016
Volume 49 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Vlčková, K., Réda, J., Ondrušová, L., Krayem, M., Ghanem, G., & Vachtenheim, J. (2016). GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax. International Journal of Oncology, 49, 953-960. https://doi.org/10.3892/ijo.2016.3596
MLA
Vlčková, K., Réda, J., Ondrušová, L., Krayem, M., Ghanem, G., Vachtenheim, J."GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax". International Journal of Oncology 49.3 (2016): 953-960.
Chicago
Vlčková, K., Réda, J., Ondrušová, L., Krayem, M., Ghanem, G., Vachtenheim, J."GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax". International Journal of Oncology 49, no. 3 (2016): 953-960. https://doi.org/10.3892/ijo.2016.3596